Enlivex (ENLV) Cash from Operations (2013 - 2025)
Enlivex (ENLV) posted quarterly Cash from Operations of 2626000.0 for Q4 2025, up 35.7% year-over-year from 1935146.88 in Q4 2024, and down 33.43% quarter-over-quarter from 1968000.0 in Q3 2025.
Enlivex (ENLV) Cash from Operations (2013 - 2025) Analysis & Trends
Enlivex's Cash from Operations history runs 13 years deep, the most recent figure standing at 2626000.0 for Q4 2025.
- In Q4 2025, Cash from Operations rose 35.7% year-over-year to 2626000.0; the TTM figure through Dec 2025 stood at 10416000.0 (up 19.93% YoY), while the FY2025 annual figure was 10416000.0, up 19.93% from the prior year.
- Cash from Operations for Q4 2025 stood at 2626000.0, down from 1968000.0 in the prior quarter.
- The five-year high for Cash from Operations was 1198000.0 in Q2 2025, with the low at 9273000.0 in Q2 2022.
- The 5-year median for Cash from Operations is 4460000.0 (2021), against an average of 4422100.0.
- The sharpest annual moves came in 2021 and 2024: Cash from Operations plunged 400.39% in 2021, then jumped 74.41% in 2024.
- Enlivex's Cash from Operations stood at 6591000.0 in 2021, then rose by 26.9% to 4818000.0 in 2022, then fell by 9.53% to 5277000.0 in 2023, then grew by 22.61% to 4084000.0 in 2024, then surged by 35.7% to 2626000.0 in 2025.
- Business Quant data shows ENLV's Cash from Operations at 2626000.0 in Q4 2025, 1968000.0 in Q3 2025, and 1198000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | -2.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.63 Mn |
| Dec 31, 2025 | -2.63 Mn |
| Sep 30, 2025 | -1.97 Mn |
| Sep 30, 2025 | -1.97 Mn |
| Jun 30, 2025 | -1.20 Mn |
| Jun 30, 2025 | -1.20 Mn |
| Mar 31, 2025 | -4.62 Mn |
| Mar 31, 2025 | -4.62 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Jun 30, 2024 | -1.80 Mn |
| Jun 30, 2024 | -1.80 Mn |
| Mar 31, 2024 | -4.51 Mn |
| Mar 31, 2024 | -4.51 Mn |
| Dec 31, 2023 | -5.28 Mn |
| Dec 31, 2023 | -5.28 Mn |
| Sep 30, 2023 | -5.44 Mn |
| Sep 30, 2023 | -5.44 Mn |